Intellia Therapeutics (NTLA) Operating Leases (2019 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Operating Leases of $61.4 million for Q1 2026, down 23.72% year-over-year from $80.5 million in Q1 2025, and down 8.16% quarter-over-quarter from $66.8 million in Q4 2025.
Intellia Therapeutics (NTLA) Operating Leases (2019 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Operating Leases for 8 consecutive years, with $61.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 23.72% year-over-year to $61.4 million; the TTM figure through Mar 2026 stood at $61.4 million (down 23.72% YoY), while the FY2025 annual figure was $66.8 million, down 64.81% from the prior year.
- Operating Leases slipped to $61.4 million in Q1 2026 per NTLA's latest filing, from $66.8 million in the prior quarter.
- Across five years, Operating Leases topped out at $190.0 million in Q4 2024 and bottomed at $60.0 million in Q2 2022.
- Historically, Operating Leases has averaged $90.6 million across 5 years, with a median of $84.1 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Leases surged 96.34% — and 2025, when it tumbled 64.81%.
- Intellia Therapeutics' Operating Leases stood at $114.0 million in 2022, then dropped by 15.15% to $96.7 million in 2023, then surged by 96.34% to $190.0 million in 2024, then sank by 64.81% to $66.8 million in 2025, then retreated by 8.16% to $61.4 million in 2026.
- Business Quant data shows NTLA's Operating Leases at $61.4 million in Q1 2026, $66.8 million in Q4 2025, and $70.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.07 Mn |
| Mar 31, 2026 | 61.40 Mn |
| Dec 31, 2025 | 66.85 Mn |
| Sep 30, 2025 | 70.59 Mn |
| Jun 30, 2025 | 75.60 Mn |
| Mar 31, 2025 | 80.49 Mn |
| Dec 31, 2024 | 189.95 Mn |
| Sep 30, 2024 | 82.45 Mn |
| Jun 30, 2024 | 87.33 Mn |
| Mar 31, 2024 | 92.10 Mn |
| Dec 31, 2023 | 96.75 Mn |
| Sep 30, 2023 | 101.26 Mn |
| Jun 30, 2023 | 105.58 Mn |
| Mar 31, 2023 | 109.80 Mn |
| Dec 31, 2022 | 114.02 Mn |
| Sep 30, 2022 | 84.10 Mn |
| Jun 30, 2022 | 60.00 Mn |
| Mar 31, 2022 | 62.48 Mn |
| Dec 31, 2021 | 64.91 Mn |
| Sep 30, 2021 | 67.27 Mn |